Delivery Order SPE2DB20D9226-SPE2DB25FQ58C

Award Date 2/21/25
Potential Completion Date 3/14/25
Potential Value $10K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The award, valued at $42,881.40, is a delivery order to provide NEXPLANON 68 MG IMPLANTS. The contract has a firm fixed-price pricing type and does not have a set-aside designation. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA valued...
This federal contract award, valued at $34,305.12, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The award is a firm fixed-price delivery order contract for NEXPLANON 68 MG IMPLANTS. DMS Pharmaceutical Group Inc. holds a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which runs through December 31, 2025. This...
This federal contract award, valued at $10,414.65, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a delivery order for the supply of NEXPLANON 68 MG IMPLANTS, a specialized pharmaceutical product, with a completion date of March 14, 2025. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $14,293.80, is a delivery order issued under DMS Pharmaceutical Group's existing $499,999,999 Indefinite Delivery Contract (IDC) with the DLA. The contract is for the delivery of 4,566,706,862 units of NEXPLANON 68 MG IMPLANTS, a specialized pharmaceutical product. The...
This federal contract award, valued at $4,288.14, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of 4,566,185,173 units of the NEXPLANON 68 MG IMPLANTS pharmaceutical product. The contract is a firm fixed-price delivery order that does not have a set-aside designation. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $10,720.35 firm fixed-price delivery order is for the supply of NEXPLANON 68 MG IMPLANTS and has an ultimate completion date of August 15, 2024. The contract is part of DMS Pharmaceutical Group's larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to...
This federal contract award, valued at $4,288.14, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order for the supply of NEXPLANON 68 MG IMPLANTS, a contraceptive product, with a performance period ending on September 26, 2024. DMS Pharmaceutical Group Inc. holds a larger indefinite delivery contract (IDC) with the DLA under the...
This federal contract award, valued at $7,146.90, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The award is a firm fixed-price delivery order for the supply of NEXPLANON 68 MG IMPLANTS, a type of contraceptive implant. This delivery order is part of a larger $499,999,999 indefinite delivery contract (IDC) that DMS Pharmaceutical Group holds with the DLA under the SPE2DB...
This federal contract award, valued at $3,775.08, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order for the supply of NEXPLANON 68 MG IMPLANTS, a contraceptive device. DMS Pharmaceutical Group Inc. holds a significant indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $4,288.14, is for the delivery of NEXPLANON 68 MG IMPLANTS to the DLA's Medical Supply Chain division. The contract is a firm fixed-price delivery order with no set-aside designation. DMS Pharmaceutical Group Inc. holds a significant indefinite delivery contract (IDC) with the...
  • SPE2DB20D9226
    Indefinite Delivery Contract
  • SPE2DB20D9226-SPE2DB25FQ58C
    Delivery Order

This federal contract award, valued at $10,414.65, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order for the provision of NEXPLANON 68 MG IMPLANTS, a specialized pharmaceutical product.

DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. This IDC enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. The contract does not have a set-aside designation.

Generated 5/23/25, 9:53 AM